Last checked at 18 Mar 2020 07:00
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Oxford Biomedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector® Platform for CAR-T and TCR-T Therapeutics
Oxford, UK - 18 March 2020: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that it has signed a new Licence and Clinical Supply Agreement ("LSA") with Juno Therapeutics, a Bristol-Myers Squibb company (NYSE: BMY). The LSA grants Juno Therapeutics a non-exclusive license to Oxford Biomedica's LentiVector® platform for its application in CAR-T and TCR-T programmes in oncology and other indications, and additionally puts in place a five year Clinical Supply Agreement, which may be extended further.
Under the terms of the LSA, Oxford Biomedica will receive an upfront payment of $10 million in cash and potentially up to $86 million upon achievement of certain development and regulatory milestones related to multiple products and indications. Oxford Biomedica is also entitled to receive up to $131 million in sales-based milestone payments and an undisclosed royalty on the net sales of products sold by Juno Therapeutics utilising the LentiVector® platform. Oxford Biomedica will also receive payments from process development and scale-up projects as well as relating to the GMP manufacture of lentiviral vectors for use in clinical trials.
As part of the LSA, Juno Therapeutics will have access to Oxford Biomedica's new 7,800 m2 commercial manufacturing centre OxBox, in Oxford, UK. Oxford Biomedica is already working on four undisclosed active projects, with Juno able to initiate additional projects in the future.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: "Juno Therapeutics, a Bristol-Myers Squibb company, is a recognised leader with an innovative pipeline in the CAR-T and TCR-T field and we are delighted to sign this new agreement with them. This new relationship with a long established leader in the CAR-T field, underlines the value of Oxford Biomedica's LentiVector® platform for leading companies. By offering world leading lentiviral vector technologies and proven clinical and commercial manufacturing capabilities, we are able to offer our partners and customers a unique suite of capabilities not found elsewhere in the industry.
"This is the second company that has committed to working with us in our new OxBox facility, which we expect to be producing GMP vector by the end of the first half 2020. Today's announcement further validates our decision taken in 2018 to invest in and scale up our GMP manufacturing facilities for clinical and commercial viral vector manufacture to support both existing and new partners and customers as well as the expected demand from industry."
-Ends-
Enquiries: |
|
Oxford Biomedica plc
John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR
|
T: +44 (0)1865 783 000 T: +44 (0)1865 783 000 T: +44 (0)1865 954 161 / E: ir@oxb.com
|
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal |
T: +44 (0)20 3709 5700 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 480 people. Further information is available at www.oxb.com
About OxBox
OxBox is Oxford Biomedica's new 7,800 m2 commercial manufacturing centre, located in Oxford, UK. Phase I, which will be operational in 2020, is 4,200 m2 of developed area consisting of six GMP clean room suites - four for vector production and two for fill-finish, warehousing and cold chain facilities and support laboratories. Phase II will provide for flexible expansion for a further six GMP clean room suites. This world class facility is expected to more than double Oxford Biomedica's manufacturing capacity, supporting further growth in revenues.
The person who arranged for the release of this announcement on behalf of Oxford Biomedica plc was John Dawson, Chief Executive Officer.